SCHEMBL467934

SCHEMBL467934

Nc1nc(Nc2ccc3c(c2)CCC(N2CCC(F)(F)CC2)CC3)n(-c2cc3c(nn2)-c2ccccc2CCC3)n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 15/20 0.66
AURKA O14965 1/20 0.66
EGFR P00533 1/20 0.66
RET P07949 1/20 0.66
MET P08581 1/20 0.66
KIT P10721 1/20 0.66
SRC P12931 1/20 0.66
PDGFRA P16234 1/20 0.66
KDR P35968 1/20 0.66
FLT3 P36888 1/20 0.66
TYRO3 Q06418 1/20 0.66
DDR1 Q08345 1/20 0.66
MERTK Q12866 1/20 0.66
AURKB Q96GD4 1/20 0.66
ALK Q9UM73 1/20 0.66
JAK2 O60674 1/20 0.33
JAK3 P52333 1/20 0.33
PTK2 Q05397 1/20 0.33
BCHE P06276 2/20 0.32
ACHE P22303 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30121612 0.92 AXL (0.77) AXLAURKAEGFRRETMET
SCHEMBL467608 0.92 AXL (0.74) AXLAURKAEGFRRETMET
SCHEMBL467825 0.92 AXL (0.77) AXLAURKAEGFRRETMET
SCHEMBL467824 0.92 AXL (0.77) AXLAURKAEGFRRETMET
SCHEMBL467730 0.91 AXL (0.75) AXLAURKAEGFRRETMET
SCHEMBL467672 0.88 AXL (0.85) AXLAURKAEGFRRETMET
SCHEMBL30121507 0.88 AXL (0.85) AXLAURKAEGFRRETMET
SCHEMBL467053 0.87 AXL (0.64) AXLAURKAEGFRRETMET
SCHEMBL467927 0.85 AXL (0.60) AXLAURKAEGFRRETMET
SCHEMBL467814 0.85 AXL (0.62) AXLAURKAEGFRRETMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2387395-A1 AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER Rigel Pharmaceuticals, Inc. (US) 2011-11-23 EP claimed
US-8040491-B2 Exposure method, substrate stage, exposure apparatus, and device manufacturing method NIKON CORPORATION (JP) 2011-10-18 US claimed
WO-2010083465-A1 AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER RIGEL PHARMACEUTICALS, INC. (US) 2010-07-22 WO claimed
EP-2387395-A1 AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER Rigel Pharmaceuticals, Inc. (US) 2011-11-23 EP disclosed
US-8040491-B2 Exposure method, substrate stage, exposure apparatus, and device manufacturing method NIKON CORPORATION (JP) 2011-10-18 US disclosed
WO-2010083465-A1 AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER RIGEL PHARMACEUTICALS, INC. (US) 2010-07-22 WO disclosed